Verici Dx Plc (GB:VRCI) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Verici Dx Plc is set to present new data at the American Transplant Congress highlighting the role of its TutiviaTM tool in assessing risks of delayed graft function in kidney transplants. The company aims to address an unmet need in identifying rejection risks, showcasing their clinical trial findings to the global transplant community. Verici Dx specializes in developing advanced diagnostics to improve outcomes for transplant patients through AI-assisted transcriptomic analysis.
For further insights into GB:VRCI stock, check out TipRanks’ Stock Analysis page.